Shawn Kwatra, MD, FAAD, physician scientist at the University of Maryland Medical System, presented data at the American Academy of Dermatology 2025 annual conference on the rapid efficacy of topical ...
Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...
The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic ...
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped ...
Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...
Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...
The world's eyes are once again on China as the annual sessions of the National People's Congress (NPC) and the Chinese ...
Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.
A new survey commissioned by Leo Pharma confirms there’s plenty of room in the market for its chronic hand eczema treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback